MedTrace Logo

Pharmacogenetic Testing and Chronic Pain

NCT05259865 · Status: SUSPENDED · Type: OBSERVATIONAL · Enrollment: 400

Last updated 2024-02-13

No results posted yet for this study

Summary

Understanding the impact of genetics could aid rational, precision drug choices. In the current study, investigators will focus on whether genetic analysis of drug processing using the Inagene platform could predict efficacy and side effect profile in patients prescribed medication for pain.

Conditions

Interventions

DIAGNOSTIC_TEST

Genetic test for drug response prediction

There is interest in whether genetic analysis of how a given drug is processed for a patient can help with rational drug choices (i.e. most efficacious, with least side effects/interactions, in the fastest time). This appears to have some early support in cardiac, psychiatric and acute pain studies. All participants enrolled in the study will provide consent and a buccal cell sample for genotyping and standard patient reported outcomes questionnaires at the beginning of the study.

Sponsors & Collaborators

  • Canadian Forces Health Services Centre Ottawa

    lead OTHER

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-09-21
Primary Completion
2026-12-31
Completion
2027-12-31

Countries

  • Canada

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05259865 on ClinicalTrials.gov